Cytokinetics (CYTK) Downgraded by Needham & Company LLC to “Buy”

Needham & Company LLC downgraded shares of Cytokinetics (NASDAQ:CYTK) from a strong-buy rating to a buy rating in a report published on Wednesday, November 29th. Needham & Company LLC currently has $12.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $22.00.

Other research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Cytokinetics from a buy rating to a hold rating in a research note on Thursday, August 17th. Cantor Fitzgerald restated a buy rating and set a $21.00 target price on shares of Cytokinetics in a report on Monday, September 18th. TheStreet cut shares of Cytokinetics from a c rating to a d rating in a report on Friday, October 27th. HC Wainwright restated a buy rating and set a $26.00 target price on shares of Cytokinetics in a report on Wednesday, September 20th. Finally, JMP Securities reaffirmed an outperform rating and issued a $13.00 price objective (down previously from $17.00) on shares of Cytokinetics in a research note on Tuesday, November 21st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $17.64.

Shares of Cytokinetics (NASDAQ CYTK) traded down $0.10 during trading hours on Wednesday, hitting $8.00. 408,955 shares of the company’s stock traded hands, compared to its average volume of 1,428,476. Cytokinetics has a 12 month low of $7.00 and a 12 month high of $17.20. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.04. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%. The business had revenue of $6.18 million for the quarter, compared to analyst estimates of $5.35 million. sell-side analysts predict that Cytokinetics will post -2.4 EPS for the current year.

In other Cytokinetics news, EVP Fady Ibraham Malik sold 7,321 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.39, for a total value of $98,028.19. Following the sale, the executive vice president now directly owns 47,540 shares in the company, valued at approximately $636,560.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Caryn Gordon Mcdowell sold 4,260 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total transaction of $55,124.40. Following the completion of the sale, the insider now owns 17,982 shares in the company, valued at $232,687.08. The disclosure for this sale can be found here. Insiders have sold a total of 34,762 shares of company stock worth $497,826 in the last 90 days. 7.20% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the company. State of Alaska Department of Revenue acquired a new stake in shares of Cytokinetics during the 2nd quarter valued at about $109,000. Birchview Capital LP acquired a new stake in shares of Cytokinetics during the 3rd quarter valued at about $145,000. Municipal Employees Retirement System of Michigan acquired a new position in Cytokinetics in the second quarter valued at about $132,000. Piedmont Investment Advisors LLC acquired a new position in Cytokinetics in the third quarter valued at about $159,000. Finally, Bank of America Corp DE boosted its position in Cytokinetics by 36.8% in the first quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 3,383 shares in the last quarter. Institutional investors and hedge funds own 73.72% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cytokinetics (CYTK) Downgraded by Needham & Company LLC to “Buy”” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/10/needham-company-llc-downgrades-cytokinetics-cytk-to-buy.html.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply